The Jetstream (JET) Post-market Registry

Inclusion Criteria: * Patient is ≥ 18 years of age. * The target de novo or restenotic Percutaneous Transluminal Angioplasty (PTA) lesion(s) is/are located in the common femoral, superficial femoral or popliteal arteries. * The reference vessel lumen (proximal to target lesion) is ≥ 4.0mm. * Evidence of ≥ 70% stenosis or occlusion confirmed by angiography. * Guidewire must cross lesion(s) within the true lumen, without a sub-intimal course before the patient is considered as entered into the study. * Patient is an acceptable candidate for percutaneous intervention using the Jetstream NAVITUS System in accordance with its labeled indications and instructions for use. * Lesion length ≥ 4cm. * Patient has a Rutherford category score of 1-3. * Patient has signed approved informed consent. * Patient is willing to comply with the follow-up evaluations at specified times. Exclusion Criteria: * Patient has an uncontrollable allergy to nitinol, stainless steel or other stent materials or to contrast agent. * Patient is unable to take appropriate anti-platelet therapy. * Patient has no patent distal runoff vessels. * Patient has critical limb ischemia (i.e., Rutherford class 4-6) * Limited vascular access that precludes safe advancement of the Jetstream NAVITUS System to the target lesion(s). * Interventional treatment is intended for in-stent restenosis. * Patient has target vessel with moderate or severe angulation (e.g., \>30 degrees) or tortuosity at the treatment segment. * Patient has a history of coagulopathy or hypercoagulable bleeding disorder. * Patient is receiving hemodialysis or has significantly impaired renal function (creatinine is \> 2.5 mg/dl) at the time of treatment. * Patient has evidence of intracranial or gastrointestinal bleeding within the past 3 months. * Patient has had severe trauma, fracture, major surgery or biopsy of a parenchymal organ within the past 14 days. * Patient has had surgical or endovascular procedure in the same vascular territory within 30 days prior to the index procedure. * Patient has any planned surgical intervention or endovascular procedure within 30 days after the index procedure. * Use of another debulking device during the index procedure prior to the Jetstream NAVITUS System will exclude the patient.